Qualigen Therapeutics Inc (QLGN) - Total Assets
Based on the latest financial reports, Qualigen Therapeutics Inc (QLGN) holds total assets worth $43.47 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Qualigen Therapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Qualigen Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Qualigen Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Qualigen Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Qualigen Therapeutics Inc's total assets of $43.47 Million consist of 100.0% current assets and 0.0% non-current assets. Review QLGN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.1% |
| Accounts Receivable | $2.01 Million | 42.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Qualigen Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Qualigen Therapeutics Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qualigen Therapeutics Inc's current assets represent 100.0% of total assets in 2024, an increase from 99.6% in 2012.
- Cash Position: Cash and equivalents constituted 25.1% of total assets in 2024, down from 95.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 42.9% of total assets.
Qualigen Therapeutics Inc Competitors by Total Assets
Key competitors of Qualigen Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Qualigen Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.83 | 0.52 | 2.71 |
| Quick Ratio | 8.83 | 0.52 | 2.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $38.55 Million | $-2.14 Million | $17.79 Million |
Qualigen Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Qualigen Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.91 |
| Latest Market Cap to Assets Ratio | 1.01 |
| Asset Growth Rate (YoY) | 130.5% |
| Total Assets | $4.69 Million |
| Market Capitalization | $4.74 Million USD |
Valuation Analysis
Above Book Valuation: The market values Qualigen Therapeutics Inc's assets above their book value (1.01x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Qualigen Therapeutics Inc's assets grew by 130.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Qualigen Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Qualigen Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.69 Million | +130.49% |
| 2023-12-31 | $2.03 Million | -89.35% |
| 2022-12-31 | $19.08 Million | -16.43% |
| 2021-12-31 | $22.84 Million | -21.60% |
| 2020-12-31 | $29.13 Million | +941.35% |
| 2019-12-31 | $2.80 Million | -81.74% |
| 2018-12-31 | $15.32 Million | -32.91% |
| 2017-12-31 | $22.83 Million | +215.52% |
| 2016-12-31 | $7.24 Million | -54.88% |
| 2015-12-31 | $16.04 Million | +441.28% |
| 2014-12-31 | $2.96 Million | +441.04% |
| 2013-12-31 | $547.71K | -70.50% |
| 2012-12-31 | $1.86 Million | -- |
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more